HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel
Titel:
HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel
Auteur:
Di Leo, A. Chan, S. Paesmans, M. Friedrichs, K. Pinter, T. Cocquyt, V. Murray, E. Bodrogi, I. Walpole, E. Lesperance, B. Korec, S. Crown, J. Simmonds, P. Von Minckwitz, G. Leroy, J.Y. Durbecq, V. Isola, J. Aapro, M. Piccart, M.J. Larsimont, D.